After a long period of delay, the Centers for Medicare & Medicaid Services (“CMS” or the “Agency”) at last released its final rule (the “Final Rule”) implementing the Physician Payment Sunshine Act (Section 6002 of the Affordable Care Act) (the “Act”) on February 1, 2013. Due to the Agency’s delay, CMS will not require applicable manufacturers to report payments occurring prior to August 1, 2013, and the first manufacturer reports made pursuant to the Act will be due to CMS by March 31, 2014.
In response to numerous comments, CMS implemented significant modifications to several of its original proposals in an attempt to streamline tracking and reporting obligations for manufacturers. For example, CMS finalized several provisions to simplify the reporting of research payments, including eliminating the proposed requirement that applicable manufacturers report research payments as direct or indirect and implementing a process by which research-related payments will be reported and published separately from other payments and transfers of value made to covered recipients. In addition, CMS has made modifications related to reporting indirect payments provided through a third party, reporting the value of food and beverages provided in group settings, delayed publication, dispute resolution, and attestation, among others.
Additional detail regarding the provisions of the Final Rule is available here.
If you have any questions about this alert, please contact:
Hae-Won Min Liao
Our Healthcare Practice represents participants in all facets of the healthcare industry, including pharmaceutical, biotech and device companies, DME suppliers, hospitals, skilled nursing facilities, physician-owned companies, professional associations and research institutions. Our lawyers combine a strong background in the complexities of healthcare financing and delivery, including coding, reimbursement, and coverage issues, privacy and security, trade regulation, and competition. We have extensive experience representing clients on enforcement and regulatory matters before federal and state enforcement agencies.
For further information on the Healthcare Practice, please contact:
On three continents, Sidley’s Global Life Sciences Practice team offers coordinated cross-border and national advice on Food, Drug and Medical Device Regulatory, Life Sciences Enforcement, Litigation and Compliance, Healthcare Regulatory, Products Liability, Intellectual Property, Corporate and Technology Transactions, Securities and Corporate Finance, International Trade and Arbitration, FCPA/Anti-Corruption, Antitrust/Competition, Environmental/Nanotechnology.
Globally rated as one of the top life sciences practices, our team includes former senior government officials, medical doctors and leaders in various life sciences fields.
For further information on the Global Life Sciences Practice, please contact:
James C. Stansel
To receive Sidley updates via email, please click here.
Sidley Austin provides this information as a service to clients and other friends for educational purposes only. It should not be construed or relied on as legal advice or to create a lawyer-client relationship.
Attorney Advertising - For purposes of compliance with New York State Bar rules, our headquarters are Sidley Austin LLP, 787 Seventh Avenue, New York, NY 10019, 212.839.5300; One South Dearborn, Chicago, IL 60603, 312.853.7000; and 1501 K Street, N.W., Washington, D.C. 20005, 202.736.8000.